HGH Fragment 176-191 Dosage: The Common Protocol and the Evidence
HGH Fragment 176-191 dosage: the 200-500 mcg common protocol, the one 1978 rat study, and why no human dose exists for this sequence.
The short version
There is no FDA-approved or trial-established human dose for HGH Fragment 176-191. Research-chemical dosing guides most often describe 200-500 mcg by subcutaneous injection, once or twice daily, fasted, in cycles of roughly 4-12 weeks. That is common practice, not something any trial established. The only controlled dosing data for this exact sequence is a single 1978 rat study, and it was not testing fat loss.
- The common protocol is 200-500 mcg, subcutaneous, once or twice daily, fasted, over a 4-12 week cycle. It is common practice, not trial-established.
- The only published dose for this exact sequence is a 1978 rat study. It used a single 5 nmol/kg dose to test insulin sensitivity, not fat loss.
- No human pharmacokinetic study, and no established half-life, exists for this sequence.
- AOD-9604's dosing history is separate and does not transfer. See the AOD-9604 dosage page for its different animal-study doses.
No trial has established a human dose of HGH Fragment 176-191. This page gives the protocol most often used in research-chemical dosing guides, labelled as common practice. It then covers what has been studied for this sequence: one 1978 rat experiment that was not measuring fat loss. Background on the compound, its relationship to AOD-9604, and its legal status is on the main guide.
US legal status - Unapproved drug
HGH Fragment 176-191 has no FDA-approved product and no approved indication or dose, and does not appear by this name on the FDA bulk drug substances compounding safety-risk page.
HGH Fragment 176-191 dosage: the common protocol
Research-chemical dosing guides most often describe 200-500 mcg by subcutaneous injection, once or twice daily, fasted, in cycles of roughly 4-12 weeks. That is common practice, not a dose any trial or regulator has established.
Common protocol
What is commonly used, not a dose established in trials. No regulator has set a dose for HGH Fragment 176-191. Sources differ, so the ranges below span them.
- Dose per administration
- 200-500 mcg
- How often
- once or twice daily, fasted
- Route
- Subcutaneous injection
- Cycle length
- 4-12 weeks
- Break between cycles
- 1 weeks
- Common vial size
- 5 mg
- Timing
- Fasted - a morning dose 20-60 minutes before eating, and/or a pre-bed dose at least 2-3 hours after the last meal.
Sources disagree on cycle structure: one describes short 4-week blocks with a 1-week washout repeated; the other describes a single longer 4-12 week run with no stated break. Neither source names a compound this is commonly paired with, so no pairing is listed. Both sources are explicit that no controlled human trial has established a dose for this unmodified sequence - the numbers here are compiled from research-chemical dosing guides, not from AOD-9604's own trial or any published pharmacokinetic study of 176-191 itself.
Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.
The common HGH Fragment 176-191 dose is 200-500 mcg, once or twice daily, fasted. From a 5 mg vial mixed with 2 mL of bacteriostatic water, 350 mcg is 14 units (0.14 mL) on a U-100 insulin syringe.
HGH Fragment 176-191 5 mg vial: units per dose
Full 5 mg vial page: mixing, doses per vial, how long it lasts →
| Water added | Concentration | 1 unit = | 200 mcg | 350 mcg | 500 mcg |
|---|---|---|---|---|---|
| 1 mL | 5 mg/mL | 50 mcg | 4 units | 7 units | 10 units |
| 2 mL | 2.5 mg/mL | 25 mcg | 8 units | 14 units | 20 units |
| 3 mL | 1.67 mg/mL | 16.67 mcg | 12 units | 21 units | 30 units |
All HGH Fragment 176-191 vial sizes: 5 mg
Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the calculator below.
How many 5 mg vials a cycle takes
| Scenario | Dose | Doses a week | Weeks | Total | 5 mg vials |
|---|---|---|---|---|---|
| Low end of the common protocol | 200 mcg | 7 | 4 | 5.6 mg | 2 |
| High end of the common protocol | 500 mcg | 14 | 12 | 84 mg | 17 |
Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.
The one study that actually tested this exact sequence
A 1978 study synthesised six C-terminal fragments of human growth hormone and tested them in normal rats Ng 1978 - Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-6., in the references below. The fragments were amino acids 172-191, 176-191, 177-191, 178-191, 179-191 and 180-191. It was not a fat-loss study. It measured blood glucose, plasma insulin and insulin sensitivity.
| Finding | Detail |
|---|---|
| Glucose and insulin | 176-191 (with 172-191, 177-191 and 178-191) produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin in rats. Two other fragments tested (179-191, 180-191) were inert. |
| Insulin sensitivity | A single dose of 5 nanomoles per kilogram of body weight of fragments containing the 178-191 sequence - a group that includes 176-191 - significantly reduced insulin sensitivity in intravenous insulin-tolerance tests. |
| Species | Normal rats |
| Route | Not specified as subcutaneous in the abstract |
That is the entire published controlled-dosing record for this exact sequence: one paper, one species, one set of outcomes. Those outcomes were a high-blood-sugar, insulin-raising effect, not a documented fat-loss result Ng 1978 - Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-6., in the references below.
How this differs from AOD-9604’s dosing evidence
AOD-9604 is the related, tyrosine-modified molecule covered on its own page. It has three peer-reviewed animal studies reporting specific doses, plus a discontinued human obesity trial whose dose was never published. See the AOD-9604 dosage page for those figures.
HGH Fragment 176-191 has neither: one 1978 rat study not aimed at fat loss, and no human trial at all. Treating the two compounds’ dosing evidence as interchangeable is the most common factual error made about this pairing.
How to reconstitute HGH Fragment 176-191
Converting a target amount into an injection volume depends on how a specific vial was reconstituted: the diluent volume and the resulting concentration. This page cannot know that for your vial. The dosage calculator works through the arithmetic. It does not choose a dose.
What is not established
- No approved dose exists, because no product under this name has completed FDA review.
- No dose has been proven safe or effective for fat loss by any regulator or trial. The only controlled figure above is from a 1978 rat study measuring glucose and insulin, not weight loss.
- No human pharmacokinetic study or established half-life exists, so no dosing interval is backed by human data.
- AOD-9604’s separate animal and trial history does not transfer to this different sequence - see the main guide for the exact molecular difference between the two.
Who should not use it
No FDA-reviewed contraindication list exists, because no human review of this compound has happened. Nobody should self-direct an unapproved research chemical with no published human data around a current medical condition, medication or pregnancy. That decision belongs with a licensed clinician.
HGH Fragment 176-191 side effects and risks
The only controlled data, the 1978 rat study above, reported a short-lived rise in blood glucose and a more sustained rise in plasma insulin. It also reported reduced insulin sensitivity at the dose tested Ng 1978 - Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-6., in the references below. Beyond that single animal study, there is no human safety data of any kind for this exact sequence and no FDA-reviewed safety label. There is also no verified content, purity or actual concentration for a vial bought outside a regulated supply chain.
Related
- HGH Fragment 176-191: how it differs from AOD-9604 and what full HGH does
- AOD-9604 dosage: the animal-study doses and the calculator
- Dosage calculator
- Research peptides and the law
HGH Fragment 176-191 dosage calculator
Preset to a 5 mg vial and 200 mcg, the low end of the common protocol. Enter your own vial size, water and dose to get the syringe units to draw.
Your vial
Printed on the vial. There is no standard size - enter what yours says.
This changes how much you draw - never how many doses the vial holds.
100 units per mL. 1 unit = 0.01 mL. This is what almost every insulin syringe sold is, in every barrel size.
Capacity only. A 1 mL U-100 syringe holds 100 units - the scale decides that, not the barrel.
Draw this much
= 0.08 mL on a 1 mL U-100 syringe
- Concentration
- 2,500 mcg/mL
- Exact volume
- 0.08 mL
- Dose you actually get
- 200 mcg
- Doses per vial(unaffected by water volume)
- 25
Where to buy HGH Fragment 176-191 for research
Each vendor is checked against my vendor checklist.
1.Next Level PharmFeatured
5 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
Common questions
What is the usual HGH Fragment 176-191 dose?
Research-chemical dosing guides most commonly describe 200-500 mcg by subcutaneous injection, once or twice daily, in a fasted state, over roughly a 4-12 week cycle. That figure is compiled from guides aimed at buyers of the research chemical. No published human trial or regulator supports it, and no trial of this exact sequence exists to establish a dose.
What dose was actually used in a study?
Only one controlled study exists for this exact sequence. A 1978 rat study gave a single dose of 5 nanomoles per kilogram of body weight of fragments containing the 178-191 sequence, a group that includes 176-191. It measured blood glucose, plasma insulin and insulin sensitivity, not fat loss. This page does not recommend that dose, and the study was not testing the effect the compound is marketed for today.
Is there an FDA-approved dose for HGH Fragment 176-191?
No. It has no FDA-approved product and does not appear by this name on FDA's bulk drug substance compounding safety-risk list. The figures on this page come from research-chemical dosing guides and one 1978 animal study, not from FDA review or an approved label.
How does this compare to AOD-9604 dosing?
In circulating protocols they are dosed similarly, both commonly described in the 200-500 mcg subcutaneous range, but the evidence behind each differs. AOD-9604 has animal dosing data from three peer-reviewed studies and a discontinued human obesity trial with no published dose. HGH Fragment 176-191 has one 1978 rat study that was not measuring fat loss at all. See the AOD-9604 dosage page for that compound's animal-study numbers.
How often and for how long is it commonly used?
Research-chemical dosing guides describe once or twice daily dosing, fasted, for roughly 4-12 weeks. Sources differ on cycle structure. One describes short 4-week blocks with a 1-week break, repeated. Another describes a single longer 4-12 week run. Neither is a trial-established schedule.
How do I work out reconstitution and injection volume?
That is arithmetic specific to a vial's concentration and diluent volume, which this page cannot know for you. Use the dosage calculator to work through the math for your vial and target amount. It performs the calculation. It does not choose a dose.
What are the main risks?
The only controlled data, a single 1978 rat study, reported a rise in blood glucose, a rise in plasma insulin and reduced insulin sensitivity at the dose tested. There is no human safety data of any kind and no FDA-reviewed safety label. A vial bought outside a regulated supply chain has no verified content or purity.
When should I stop and get medical care?
Call 911 in the US for signs of a severe allergic reaction (swelling of the face, lips, tongue or throat, or difficulty breathing). Also call for any severe or rapidly worsening symptom after an injection. Call Poison Control at 1-800-222-1222 if you have taken an unknown or excessive amount of anything sold as HGH Fragment 176-191. This page is not a substitute for a clinician who knows your history.
References (3 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-6.StudyPMID 645904
- 2.FDA - Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. HGH Fragment 176-191 does not appear on this page by that name; the related AOD-9604 sequence does.- US Food and Drug Administrationregulatory
- 3.America's Poison Centers - confirms 1-800-222-1222 as the national Poison Control number, free and confidential, 24 hours a day.- America's Poison Centersother